Biotech Touched New Lows: ArQule, Inc. (NASDAQ:ARQL), Ova Science (NASDAQ:OVAS), Uniqure NV (NASDAQ:QURE), Egalet Corp (NASDAQ:EGLT)

ArQule, Inc. (NASDAQ:ARQL) reported a loss of 10 cents per share in the fourth quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 13 cents per share. The company had reported a loss of 9 cents in the year-ago quarter. Revenues plummeted 55.8% to $2.3 million in the fourth quarter of 2013, but surpassed the Zacks Consensus Estimate of $2 million. ArQule, Inc. (NASDAQ:ARQL) shares after opening at $1.69 moved to $1.75 on last trade day and at the end of the day closed at $1.66. Company price to sales ratio in past twelve months was calculated as 11.42 and price to cash ratio as 6.62. ArQule, Inc. (NASDAQ:ARQL) showed a negative weekly performance of -11.70%.

Ovascience (NASDAQ:OVAS) had its price target increased by Leerink Swann to $16.00 in a research report sent to investors on Thursday morning, Analyst Ratings News reports. Ova Science Inc (NASDAQ:OVAS) shares fell -4.77% in last trading session and ended the day on $7.78. OVAS return on equity ratio is recorded as -57.00% and its return on assets is -53.90%. Ova Science Inc (NASDAQ:OVAS) yearly performance is -21.57%.

uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, announced the appointment of Eric Goossens as its new Chief Operating Officer with a primary responsibility for manufacturing and project management. Mr. Goossens has a 15-year track record of management and leadership in technology-based companies, including the biopharmaceutical industry, with particular experience in the oversight of operations and site management. In addition, uniQure welcomed Deya Corzo, M.D., in the position of Vice President, Medical Affairs for the United States as of April 1, 2014. Uniqure NV (NASDAQ:QURE) shares moved down -1.15 % in last trading session and was closed at $9.00, while trading in range of $ 8.51 – 9.10. Uniqure NV (NASDAQ:QURE) year to date (YTD) performance is -38.40%.

Egalet Corp (NASDAQ:EGLT), has announced positive results for Phase 1 study of its Egalet-001, an abuse deterrent oral morphine product that is being developed for the treatment of severe chronic pain. Egalet-001 uses Eaglet’s proprietary technology which is designed to prevent any physical and chemical manipulation. Egalet Corp (NASDAQ:EGLT) weekly performance is -20.00%. On last trading day company shares ended up $9.84.Egalet Corp (NASDAQ:EGLT) distance from 50-day simple moving average (SMA50) is -23.35%. Analysts mean target price for the company is $19.67.